Clinical Significance of OX40 and OX40 Ligand in the Peripheral Blood of Patients with Myasthenia Gravis

Table 8

Univariate and multivariate logistic regression risk models of the risk of relapse of MG (soluble molecules).

Variables	Univariate analysis		Multivariate analysis
	HR (95% CI)	value	HR (95% CI)	value
sOX40 (pg/ml)	1.018 (1.005-1.031)	0.008	1.008 (0.981-1.037)	0.562
sOX40L (ng/ml)	1.391 (1.171-1.652)	≤0.001	1.344 (1.011-1.787)	0.042
Sex, (%)
Male	Ref
Female	0.673 (0.241-1.884)	0.451
Age	1.023 (0.991-1.056)	0.168
Follow-up (month)	1.001 (0.995-1.008)	0.681
MGFA classification
OMG	Ref
GMG	19.000 (4.705-76.727)	≤0.001	8.743 (1.185-64.488)	0.033
Thymoma
Without	Ref
With	3.267 (1.173-9.096)	0.023	4.808 (0.678-34.120)	0.116
AchR-Ab (nmol/L)	1.247 (1.098-1.415)	0.001	1.134 (0.920-1.398)	0.240
Treatment
Glucocorticoid	Ref
Immunosuppressant	3.500 (1.209-10.131)	0.021	0.166 (0.030-0.928)	0.041

Abbreviations: OMG: ocular myasthenia gravis; GMG: generalized myasthenia gravis; MGFA: Myasthenia Gravis Foundation of America; AchR-Ab: acetylcholine receptor antibodies.